Pediatrix Medical Group (MD) to Release Earnings on Friday

Pediatrix Medical Group (NYSE:MD) is scheduled to be releasing its earnings data before the market opens on Friday, November 1st. Analysts expect Pediatrix Medical Group to post earnings of $0.35 per share for the quarter. Persons that wish to listen to the company’s earnings conference call can do so using this link.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.31 by $0.03. Pediatrix Medical Group had a positive return on equity of 10.59% and a negative net margin of 12.58%. The firm had revenue of $504.30 million during the quarter, compared to the consensus estimate of $505.49 million. During the same period last year, the business posted $0.37 EPS. Pediatrix Medical Group’s quarterly revenue was up .7% on a year-over-year basis. On average, analysts expect Pediatrix Medical Group to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Pediatrix Medical Group Stock Performance

NYSE MD opened at $12.57 on Friday. Pediatrix Medical Group has a 1-year low of $6.62 and a 1-year high of $12.99. The company has a market capitalization of $1.08 billion, a P/E ratio of -4.15, a PEG ratio of 2.00 and a beta of 1.56. The business has a 50 day moving average price of $11.36 and a 200 day moving average price of $9.25. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38.

Analyst Upgrades and Downgrades

MD has been the topic of a number of research analyst reports. Jefferies Financial Group upgraded Pediatrix Medical Group from a “hold” rating to a “buy” rating and lifted their target price for the company from $8.00 to $14.00 in a report on Thursday, September 26th. Truist Financial boosted their price objective on Pediatrix Medical Group from $10.00 to $13.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. UBS Group boosted their price objective on Pediatrix Medical Group from $9.00 to $10.50 and gave the stock a “neutral” rating in a research note on Friday, August 9th. Finally, StockNews.com upgraded Pediatrix Medical Group from a “sell” rating to a “hold” rating in a research note on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.90.

Insiders Place Their Bets

In other news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CEO James D. Swift sold 11,100 shares of Pediatrix Medical Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $10.79, for a total transaction of $119,769.00. Following the sale, the chief executive officer now directly owns 170,001 shares of the company’s stock, valued at approximately $1,834,310.79. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Laura A. Linynsky sold 7,000 shares of Pediatrix Medical Group stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total value of $78,120.00. Following the sale, the director now directly owns 30,805 shares in the company, valued at approximately $343,783.80. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 68,100 shares of company stock worth $701,889 over the last quarter. 2.00% of the stock is owned by corporate insiders.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.